Vinblastine, cisplatin and bleomycin treatment of advanced nonseminomatous testicular tumors

Neoplasma. 1990;37(4):445-50.

Abstract

Between December 1979 and July 1986, 190 patients with nonseminomatous germ-cell testicular tumors were treated according to the modified Einhorn scheme. The response rate was 67.89%. The most favorable results were found in the embryonal histologic type (RR = 76.9%), in the biological marker (AFP, HCG) negative (RR = 97.43%) and in the minimal pulmonary extent group (RR = 94.12%).

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / adverse effects
  • Bleomycin / therapeutic use
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Testicular Neoplasms / drug therapy*
  • Vinblastine / adverse effects
  • Vinblastine / therapeutic use

Substances

  • Bleomycin
  • Vinblastine
  • Cisplatin

Supplementary concepts

  • PVB protocol